<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Commenti a: Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy 	</title>
	<atom:link href="https://www.newpharmaitaly.it/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-spain-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-spain-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Thu, 14 May 2020 18:06:33 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
</channel>
</rss>
